A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei by Bibi, R et al.
A specific cadherin phenotype may characterise the disseminating
yet non-metastatic behaviour of pseudomyxoma peritonei
R Bibi
1, N Pranesh
1,2, MP Saunders
3, MS Wilson
2, ST O’Dwyer
2, PL Stern
1 and AG Renehan*,2
1Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Manchester, UK;
2Department of Surgery, Christie Hospital NHS Trust,
Manchester, UK;
3Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK
Pseudomyxoma peritonei (PMP) is a rare neoplasm of mainly appendiceal origin, characterised by excess intra-abdominal mucin
production leading to high morbidity and mortality. While histological features are frequently indolent, this tumour disseminates
aggressively throughout the abdominal cavity, yet seldom metastasises. This study determined the expression of several markers of
colorectal differentiation (carcinoembryonic antigen (CEA), cytokeratins (CK20 and CK7), epithelial membrane antigen), mucin
production (MUC-2, interleukin-9 (IL-9), IL-9 receptor (IL-9Ra)), and cell adhesion (N- and E-cadherin, vimentin) in PMP tissue
(n¼26) compared with expressions in normal colonic mucosa (n¼19) and colorectal adenocarcinoma (n¼26). Expressions of
CEA and cytokeratins were similar for PMP as those in colorectal adenocarcinomas with the exception that the CK20 /CK7 
pattern was rare in PMP (Fisher’s exact test: P¼0.001). Similarly, expressions of mucin-related proteins were comparable for
adenocarcinoma and PMP, with the exception that IL-9 expression was uncommon in adenocarcinoma (P¼0.009). Pseudomyxoma
peritonei demonstrated a specific pattern of adhesion-related protein expressions of increased N-cadherin, reduced E-cadherin, and
increased vimentin (P¼0.004), a phenotype suggesting a possible epithelial–mesenchymal transition state. Primary PMP cell cultures
were successfully maintained and demonstrated marker expressions similar to those seen in in vivo tissues. These early
characterisation studies demonstrate similarities between PMP and colorectal adenocarcinoma, but also reveal a specific cadherin
phenotype that may characterise the distinct non-metastasising behaviour of PMP, and form the basis for future mechanistic and
therapy-targeting research.
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Pseudomyxoma peritonei (PMP) is a rare neoplasm (one per
million population per year) defined by disseminated peritoneal
mucinous tumour deposition and progressive accumulation of
mucinous ascites (Hinson and Ambrose, 1998; Esquivel and
Sugarbaker, 2000; Bryant et al, 2005). At a clinical level, PMP is
characterised by a tendency to progress despite surgery, with
ultimate high mortality. There are three pathological types: (i)
disseminated peritoneal adenomucinosis (DPAM), the commonest;
(ii) peritoneal mucinous carcinomatosis with intermediate and/or
discordant features (PMCA-I/D); and (iii) peritoneal mucinous
carcinomatosis (PMCA), with respective 5-year age-adjusted
survival rates of 84, 38, and 7% (Ronnett et al, 1995b).
Originally thought to be of ovarian origin, it is now widely
accepted that the appendix is the source of neoplasia in PMP
(Hinson and Ambrose, 1998; Esquivel and Sugarbaker, 2000).
While the appendiceal lesion often maintains indolent histological
features, the disease may disseminate aggressively throughout the
abdominal cavity, but notably seldom metastasises. The accumula-
tion of extracellular mucin is central to the pathogenesis of the
disease and contributes to its morbidity and mortality. However,
because of its rarity, the molecular investigation of this disease has
been scarce (Mohamed et al, 2004).
In the United Kingdom, since 2001, the Department of Health
have centralised the management of PMP to two centres
(Sugarbaker, 2006), offering opportunities for the collection of
tissue samples to undertake early characterisation studies.
This study aimed to investigate markers that might be relevant
to the pathology and progression in PMP. The expression patterns
of markers such as the carcinoembryonic antigen (CEA),
cytokeratins (CK20 and CK7), and epithelial membrane antigen
(EMA) were primarily determined as these reflect the origin of
disease. To address the specific feature of excess extracellular
mucin production, we determined the differential expression of
MUC-2, a mucin with gel-forming physicochemical properties
similar to those exhibited by PMP (Kim and Gum, 1995), as well as
interleukin-9 (IL-9) and its receptor (IL-9Ra), as IL-9 has been
implicated in mucin-producing conditions such as cystic fibrosis
(Hauber et al, 2003) and asthma (Louahed et al, 2000). To
evaluation the features of PMP dissemination, we determined the
expression of molecules involved in cell adhesion and invasion,
specifically N- and E-cadherin, and vimentin, as these are
important in colorectal (Dorudi et al, 1993; Rosivatz et al, 2004)
and other carcinomas (Bringuier et al, 1993; Islam et al, 1996;
Hazan et al, 1997; Rubin et al, 2001). In particular, we sought to
determine the phenotype of N-cadherinþ/E-cadherin /vimentinþ,
as this has been implicated in epithelial–mesenchymal transition
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s(EMT) (Tran et al, 1999), a process important in the progression of
neoplasia towards dedifferentiation and more ‘malignant’ states
(Thiery, 2002). To these ends, studies were undertaken in in vivo
tissues (normal colon, colorectal cancer, PMP) and in vitro
primary derived PMP cell lines.
MATERIALS AND METHODS
Patients
Following local ethical approval (LREC-02/051), tissues were
collected from patients undergoing surgery at the Christie Hospital
NHS Trust, Manchester, UK, between 2001 and 2004. There were
three tissue groups – normal colonic mucosa (n¼19), colorectal
adenocarcinoma (n¼26), and PMP (n¼26) – with demographic
and clinicopathological characteristics as listed in Table 1.
Formalin-fixed, paraffin-embedded tissue blocks were prepared
for immunohistochemistry at the Paterson Institute for Cancer
Research (PICR). Samples of histologically normal colonic
mucosa were taken 410cm from tumours in patients undergoing
colorectal resection, and orientated to obtain a maximum number
of longitudinal crypts before final embedment (Renehan et al,
2002). All colorectal adenocarcinoma samples were from patients
undergoing primary surgical resection without preoperative
chemotherapy and/or radiation therapy, and without a histological
diagnosis of mucinous adenocarcinoma. Fifteen of the adeno-
carcinoma group formed paired samples with the normal colonic
mucosa group. For PMP tissue, wherever possible, the primary
appendiceal neoplasm was used (n¼14) but where not available
(due to prior appendicectomy), cellular elements of PMP were
judged on multiple haematoxylin- and eosin-stained sections from
other sites to identify the most representative block.
Immunohistochemistry
Antibodies were selected to examine three broad groups of
markers – tissue differentiation, mucin production, and cell
adhesion – and their suitability for formalin-fixed, paraffin-
embedded tissue as shown in Table 2.
Five-micrometre-thick sections were cut and deparaffinised in
graded alcohols and xylene. The sections were then subjected to
immunostaining, applying a standard avidin–biotin–peroxidase
method by hand as described elsewhere in experiments from the
PICR (Starzynska et al, 1997; Wilson et al, 2000). Before Ki-67 and
vimentin immunostaining, antigen retrieval was carried out by
boiling the sections in citrate buffer (pH 6.0) for 2 10min using a
microwave oven. For all antibodies, staining was completed with
2–3min incubation with diaminobenzidene using the substrate-
chromogen solution supplied in the EnVisiont HRP kit (DAKO,
Cambridge, UK). Slides were counterstained with haematoxylin
and reviewed. Appropriate positive and negative controls were
used throughout (webappendix).
Scoring of immunostaining
Immunostaining was scored semiquantitatively using the immuno-
histochemical score (IHS) method of assessment, a method shown
to have a high level of inter-laboratory correlation (Rhodes et al,
2000) and to approximate data generated from image analysis-
based scoring systems (Remmele and Schicketanz, 1993). For each
section, the IHS was the addition of the staining intensity (zero,
no staining; 1, weak; 2, moderate; 3, strong) and percentage of
positive tumour cells (0, none; 1 for 1–25%; 2 for 26–50%; 3 for
51–75%; 4 for 76–100%) with a range of 0–7 for each specimen.
An IHS value X2 was considered positive. Because of the sparse
epithelial nature of PMP, a learning set of six samples was
used to explore histopathological features and their associated
immunostaining before the main study. In addition, owing to
the high mucin component, epithelial cells were identified by
Table 1 Baseline characteristics
Normal
colonic
mucosa Adenocarcinoma PMP
a
No. of samples 19 26 26
Median age (range) 70 (32–86) 71 (36–94) 56 (33–84)
b
male:females 8:11 11:15 5:21
Staging
Early (Dukes’ A and B) — 17 (65) —
Advanced (Dukes’ C and D) — 9 (35) —
Degree of differentiation
Well — 5 (19) —
Moderate — 16 (62) —
Poorly — 5 (19) —
PMP classification
DPAM — — 20 (77)
PMCA — — 6 (23)
Unless otherwise stated, values in parentheses are percentages. PMP¼pseudo-
myxoma peritonei; RT¼radiotherapy; DPAM¼disseminated peritoneal adeno-
mucinosis; PMCA¼peritoneal mucinous carcinomatosis.
aTreatment of patients with
PMP: 10 cytoreductive resections with hyperthermic intra-operative chemotherapy;
16 debulking laparotomies.
bPseudomyxoma peritonei patients were significantly
younger compared with the other groups (Kruskal–Wallis test; P¼0.004).
Table 2 Antibodies used for immunostaining
Antibody Dilution Antigen Main specificity Source
Parlam 1:2000 CEA Gastrointestinal tract epithelium DAKO, Cambridge, UK
Ks 12.8 1:100 CK20 Colonic epithelium DAKO, Cambridge, UK
OVTL 12/30 1:80 CK7 Glandular epithelium/rectal epithelium Abcam, Cambridge, UK
E29 1:100 EMA Epithelial membrane DAKO, Cambridge, UK
Ccp58 1:100 MUC-2 Mucin-secreting cells including goblet cells Abcam, Cambridge, UK
Polyclonal 1:200 IL-9 Mucin-producing epithelium Biogenesis, Poole, UK
33401 1:100 IL-9Ra Mucin-producing epithelium R&D Systems Inc., Minneapolis, MN, USA
MIB-1 1:100 Ki-67 Cell cycle except G0 DAKO, Cambridge, UK
32 1:100 N-cadherin Inter-cellular adhesion molecules BD Transduction Laboratory, Franklin Lakes, NJ, USA
NCH-38 1:100 E-cadherin Inter-cellular adhesion molecules DAKO, Cambridge, UK
Vim 9 1:2000 Vimentin Mesenchymal cells Abcam, Cambridge, UK
PMP¼pseudomyxoma peritonei; CEA¼carcinoembryonic antigen; CK¼cytokeratin; EMA¼epithelial membrane antigen; MUC¼mucin-secreting gene product;
IL¼interleukin.
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intra-observer agreement was 73% (based on 40 specimens stained
for E-cadherin; k¼0.628, s.e.¼0.085) and inter-observer agree-
ment ranged from 66 to 86% (based on two independent
investigators, RB and NP, scoring all specimens stained for IL9Ra:
k¼0.571, s.e.¼0.059, and N-cadherin: k¼0.776, s.e.¼0.072).
Establishment of PMP cell lines
Pseudomyxoma peritonei cell cultures were established from intra-
abdominal diseased tissue, paired with controls cultured from skin
obtained from tissue excised around the laparotomy scar. Cellular
elements were finely minced using a sterile scalpel and pipetted
into small aggregates. These were seeded either into six-well plates
containing minimal medium (DMEM; 10% FCS; L-glutamine
(2mM); penicillin–streptomycin (0.1mgml
 1)) or ALC-4 serum-
containing medium (RPMI 1640; 10% FCS; L-glutamine (2mM);
penicillin–streptomycin (0.1mgml
 1); insulin (0.02mgml
 1);
transferrin (0.01mgml
 1); sodium selenite (25nM); hydrocorti-
sone (50nM); epidermal growth factor (1ngml
 1); ethanolamine
(0.01mM); phosphorylethanolamine (0.01mM); tri-iodothyronine
(0.1nM); HEPES (10mM); sodium pyruvate (0.5mM)), a fully
defined medium formulated for the selective growth of
human lung adenocarcinoma cells (Brower et al, 1986). The
cells were subsequently cultured at 371Ci n5 %C O 2 changing
half of the medium every 2–3 days. The cultures were first split
after 3–4 weeks, and thereafter passaged at this time interval
at 1:2 ratios.
Immunocytochemical analysis
Paraffin-embedded blocks were prepared from PMP cell cultures
taken from passages 6 and 10, which were washed with PBS and
fixed with formalin overnight. In addition, cells were cultured on
eight-well chamber slides from passages 6 and 10 until cells
were 80% confluent, washed with PBS, and fixed with 4%
paraformaldehyde for 15min. The DAB–peroxidase system
(DAKO, Cambridge, UK) was used for immunocytostaining using
the same panel of antibodies as described above.
Statistical analysis
SPSS version 14.0 (Superior Performing Software Systems,
Chicago, IL, USA) statistical program was used for statistical
analyses. Categorical data, for example, proportions of positive
tumours per group, were compared using the w
2 and Fisher’s exact
tests as appropriate. The IHS scores were ordinal and were
presented as turnip plots using the turnip command in STATA
version 8.2 (College Station, TX, USA), and compared using the
Mann–Whitney U-test. Paired comparisons were performed using
the Wilcoxon signed rank test. As there were multiple compar-
isons, only P-values o0.01 were considered to be statistically
significant.
RESULTS
Immunopositivity for in vivo tissue
The immunopositivities for normal colonic mucosa, colorectal
adenocarcinoma, and PMP tissues for markers of tissue differ-
entiation and mucin production are shown in Table 3. Expressions
of CEA and CK20, with absent CK7, was universal in well-
orientated normal colonic mucosa. Expression of CEA was also
universal among adenocarcinomas and present in all but one PMP
specimen. The patterns of combined CK20 and CK7 were similar
for adenocarcinomas and PMP, with the exception that the
CK20 /CK7  pattern was not seen in PMP tissue series (Fisher’s
exact test: P¼0.001).
At least some MUC-2 immunopositivity was noted in all three
tissue groups, reflecting the presence of goblet cells. Similarly, the
Table 3 Comparison of immunopositivities for markers of tissue differentiation and mucin production
No. of cases (%)
Normal colonic mucosa Adenocarcinoma PMP P value
a P value
b
Baseline CEA/cytokeratin
CEA+ 19 (100) 26 (100) 25 (96) NA 1.0
CK20+/CK7+ 0 3 (11) 8 (31) 0.01 0.17
CK20+/CK7  19 (100) 12 (46) 17 (65) 0.006 0.16
CK20 /CK7+ 0 1 (4) 1 (4) 1.0 1.0
CK20 /CK7  0 10 (39) 0 NA 0.001
EMA 19 (100) 25 (100)
c 24(100)
c NA NA
Mucin-associated proteins
MUC-2 19 (100) 26 (100) 26 (100) NA NA
IL-9 3 (16) 2 (8) 11 (42) 0.10 0.009
IL-9Ra 19 (100) 25 (96) 25 (96) 1.0 1.0
Adhesion-related proteins
N-cadherin 1 (5) 12 (46) 17 (68)
d o0.001 0.11
E-cadherin 19 (100) 26 (100) 20 (80)
d 0.06 0.02
Vimentin 0 0 8 (36) 0.01 0.004
Early Advanced DPAM PMCA
N-cadherin 5 (29) 7 (78) 12 (63)
d 5 (83)
E-cadherin 17 (100) 9 (100) 15 (79)
d 5 (83)
Vimentin 0 0 6 (30) 2 (33)
Values in parentheses are percentages. PMP¼pseudomyxoma peritonei; CEA¼carcinoembryonic antigen; CK¼cytokeratin; EMA¼epithelial membrane antigen;
MUC¼mucin-secreting gene product; IL¼interleukin; DPAM¼disseminated peritoneal adenomucinosis; PMCA¼peritoneal mucinous carcinomatosis.
aComparison of
PMP with normal colonic mucosa. w
2 test and Fisher’s exact tests as appropriate.
bComparison of PMP with adenocarcinoma. w
2 test and Fisher’s exact tests as appropriate.
cMissing data: one adenocarcinoma; two PMP cases.
dMissing data: one PMP case.
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However, IL9 expression was relatively uncommon in adeno-
carcinoma compared with PMP tissue (P¼0.009).
Expression of N-cadherin was almost absent in normal colonic
mucosa, increased in adenocarcinoma (46%), and present in over
two-thirds (68%) of PMP tissues (Po0.001). There was a
suggestion that expression was increased in advanced adeno-
carcinomas compared with early tumours, but sample numbers
were small. By contrast, expression of E-cadherin expression was
universal in normal and adenocarcinoma tissues, but reduced in
PMP tissue (80%). Expression of vimentin was absent in normal
and adenocarcinoma tissues, but present in over a third (36%) of
PMP tissues (P¼0.004).
Immunohistochemical scores
To further explore the relative differences between normal colonic
mucosa, colorectal adenocarcinoma, and PMP, IHS medians were
compared (Figure 1). Not unexpectedly, Ki-67 IHS median was
significantly increased in adenocarcinomas (Po0.001) compared
with normal colonic mucosa; in turn, PMP IHS median was similar
to that for normal mucosa. Consistent with the clinicopathological
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Figure 1 IHS scores for expression of Ki-67, MUC-2, IL9, IL9 receptor, N-cadherin, E-cadherin, and Vimentin in normal colonic mucosa, adenocarcinoma
and PMP tissues. The intensity of staining was evaluated using the IHS method of assessment. The intensity of staining was recorded as follows: 0, negative
(no staining); 1, weak; 2, moderate; 3, strong (strikingly positive). The proportion of cells in the PMP component showing positive staining was recorded as
follows: 0, none; 1, approximately 1–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%. The score for intensity was added to the score for proportion, giving the
IHS score, with a range of 0–7 for each specimen. Plots were generated using the turnip command in STATA (version 7). Comparisons of IHS scores used
Mann–Whitney U independent tests and P-values (two-sided) expressed above each comparison in the figure. Among the samples of normal colonic
mucosa and adenocarcinoma, there were 15 paired samples and were compared using the Wilcoxon signed rank test. Where independent tests were
statistically significant, the paired tests were as follows: N-cadherin, P¼0.05; E-cadherin, P¼0.004; Ki-67, P¼0.001.
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MUC-2 expression was increased in PMP tissue compared with
adenocarcinoma (Po0.001).
For the cell adhesion-related proteins, a specific phenotype
emerged. N-cadherin expression was significantly raised in
adenocarcinoma specimens compared with normal mucosa
(P¼0.003), and was similarly raised in PMP tissue (Po0.001).
Although E-cadherin immunostaining was broadly positive in all
three groups, the IHS scoring demonstrated a stepwise reduction
in expression from normal mucosa to adenocarcinoma (P¼0.004),
and from adenocarcinoma to PMP (P¼0.006). The IHS scoring
confirmed that vimentin expression was significantly increased in
PMP tissue (P¼0.004).
Pseudomyxoma peritonei in vitro cell lines
Primary cultures were successfully established in PMP samples
from 17 patients, grown for at least three passages, and recoverable
from cryopreservation. Four lines were maintained in culture for
over 12 months. Early passages (from 1 to 10) were characterised
by two cell types: an adherent layer of ‘fibroblastic-like cells’ and
a weakly adherent grape-like cluster cell colony. When the latter
were isolated, selected, and seeded, the two cell types were
reformed. By contrast, where skin cultures were established, all 17
showed a uniform fibroblastic morphology with no grape-like
cluster colonies (Figure 2A and B).
Mucin was demonstrated by Alcian blue–periodic acid–Schiff
staining (pH 2.5) in both in vivo and in vitro settings, suggesting
that the cultured PMP cells produce mucin. The labelling for
mucin in PMP cultures was associated with both the grape-like cell
colonies and most of the fibroblastic-like cells. A cell pellet
preparation from a PMP17 line at passage 5 stained with
haematoxylin and eosin revealed the typical goblet cell morpho-
logy, which compares well with the original PMP ‘tumour’ section
(Figure 2C and D).
The cultured PMP cells did not express CK20, CEA, or
E-cadherin (n¼4), even though the primary samples in vivo were
positive for these markers. However, the cultured PMP cells from
passages 6 and 10 showed heterogeneous expression of CK7 and
MUC-2, whereas the matched autologous scar wound fibroblast
cells were negative for both markers (Figure 3). The MUC2
expression in the cultured PMP cells demonstrates the mucin-
producing ability of these cells. All four PMP cultures and their
matched wound fibroblast cells expressed N-cadherin and
vimentin with the exception of PMP15 culture, which was negative
for vimentin.
DISCUSSION
Since its original description by Rotikansky in 1842 (Weaver,
1937), much of the study of PMP has focused on debates of origin
(Ronnett et al, 1995a) and degree of malignancy (Seidman et al,
1993; Misdraji et al, 2003), and more recently, on the merits of
aggressive cytoreductive surgery (Bryant et al, 2005; Sugarbaker,
2006). Because of its rarity, there have been few studies exploring
its molecular characteristics. This study determined the expression
of four marker groups – differentiation, cell proliferation, mucin
secretion, and cell adhesion – using normal colonic mucosa and
colorectal adenocarcinomas as comparators. The most striking
finding was the presence of specific cadherin and vimentin
phenotype. Specifically, normal colonic epithelium is characterised
Fibro blast cells
Cell grape-
  like clusters
"Fibroblastivc-
like" cells
Mucin
Epithelial cells
AB
CD
Figure 2 Primary cultures of diseased PMP tissue and paired abdominal
skin. Phase-contrast images of the cell cultures grown in the enriched ALC-
4 medium. (A) Fibroblast cells grown in skin. (B) PMP culture at early
passage 2 showing the two cell types – ‘fibroblastic’ cell type and grape-like
clusters. One of the PMCA (PMP12) cultures grew well until passage 12,
thereafter we observed that the grape-like cell clusters were lost and only
fibroblastic-like cells grew to passage 15 and then senesced; the other
(PMP17) continued to grow well and maintained the two cell types. PMP15
and PMP16 cultures were established from DPAMs and became senescent
at passages 8 and 12, respectively. (C) Haematoxylin- and eosin-stained
section demonstrating typical features of adenomucinosis ‘epithelium’
surrounded by a pool of mucin. (D) Cell pellet preparation of primary PMP
cell culture from the same patient as (C), illustrating the same phenotype as
the in vivo specimen ( 100 magnification).
CK20 CK7 MUC-2
0 0
1
2
3
4
5
6
7
IHS
P6 P10 S10 P6 P10 S10 P6 P10 S10
N-cadherin E-cadherin Vimentin
0 0
1
2
3
4
5
6
7
IHS
P6 P10 S10 P6 P10 S10 P6 P10 S10
A B C
Figure 3 Paraffin-embedded sections of cell pellet preparations from a
primary PMP cell culture and immunocytochemical analyses. (A) Isotype
control IgG1 showing no immunostaining. (B) Positive MUC-2 staining of
cultured PMP cells. (C) Positive CK7 staining of cultured PMP cells ( 100
magnification). Plots for immunocytochemical staining for CK20, CK7,
MUC-2 (middle panel) and N-cadherin, E-cadherin, vimentin expression
(lower panel) in four PMP lines stained at 6 weeks (P6) and 10 weeks (P10)
compared with paired skin lines at 10 weeks (S10). IHS: immunohisto-
chemical score.
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expression; adenocarcinoma is characterised by increased N-
cadherin expression in a stepwise manner with advancing stage
(Rosivatz et al, 2004), but minimal vimentin expression; and PMP
has high expression of N-cadherin and reduced E-cadherin
expression. This cadherin phenotype is suggestive of an EMT
state, a process important in the progression of neoplasia towards
dedifferentiation and more ‘malignant’ states. Additionally, the
epithelium of a third of PMP tumours expressed vimentin, usually
a marker of mesenchymal cells such as fibroblasts, but also
interpreted as the hallmark of EMT as cell–cell and cell–
extracellular matrix interactions are altered with switching of
epithelial cell to mesenchymal phenotypes (Chen et al, 2005).
These observations may explain one of PMP’s unique behaviours –
its ability to disseminate widely throughout the abdominal cavity,
often aggressively, but seldom metastasise either to nodal or
distant sites.
There are two notable limitations in the interpretation of these
findings. Firstly, the sample sizes were relatively small, prohibiting
subgroup analyses. Previous studies have shown correlations of
increased N-cadherin/reduced E-cadherin expression with advan-
cing stage (Rosivatz et al, 2004) and tumour grade (Bendardaf
et al, 2005) in colorectal adenocarcinomas. The former was partly
observed in this series, and is being addressed in ongoing studies.
Secondly, this study did not measure mRNA expression. However,
studies have shown that the expression of cadherin proteins in
colorectal tissue is closely correlated with respective gene
expression (Dorudi et al, 1993).
Advantages of the study include a PMP dedicated research
programme, within a single treatment centre, affording a well-
characterised clinicopathological data set with uniformity of
staging and pathological reporting. Additionally, as a forerunner
to the immunohistochemical experiments, a learning set of PMP
samples was used to explore histopathological features and their
associated immunostaining. This is crucial, as the cellular
components on PMP may be sparse and many sections may be
required to establish a representative sample in a given patient. For
the first time, this study established PMP cell lines that were
representative of the disease and could be maintained in culture
for more than 1 year. The cell lines shared the in vivo phenotype
expressing MUC-2, CK7þ, and vimentin, but in contrast to the
prevalent PMP phenotype, did not express CEA or CK20 and only
showed weak expression of EMA. The reasons for these differences
are not clear. All but one of the PMP specimens expressed CK20 in
vivo, supporting an intestinal origin, yet failed to express this
marker in vitro. The distinct regulation of these markers could
reflect differences of in vitro culture conditions versus in vivo
expression. The PMP cell lines also strongly expressed N-cadherin,
and interestingly, demonstrated both fibroblastic and mucin-
secreting cell types on phase contrast, reminiscent of the
observations of Islam et al (1996) for a squamous cell carcino-
ma-derived cell line that overexpressed N-cadherin. The ability to
reproducibly establish and maintain PMP cell cultures will serve as
a valuable tool to explore the molecular basis of PMP in future
studies.
In addition to cell adhesion molecules, this study also examined
other groups of molecules relevant to PMP pathology. Consistent
with the theory that the majority of PMP are colorectal in origin,
all PMP tissues were CEA positive, and all but one was CK20
positive. Similar to other studies, this study showed that the
CK20 /CK7þ pattern is rare in colorectal adenocarcinomas (and
then only found in rectal mucosal lesions) (Lagendijk et al, 1999;
Hernandez et al, 2005), and this extends to PMP specimens. The
reporting of CK20 positivity is variable in normal colonic
epithelium as it is necessary (as in the current study) to have
well-orientated mucosal sections to demonstrate staining in cells in
the outer differentiated zone of the intestinal crypt (Hernandez
et al, 2005). As in other studies (O’Connell et al, 2002; Mohamed
et al, 2004), we demonstrated increased expression of MUC-2 in
PMP tissue compared with normal mucosa and adenocarcinoma.
Interleukin-9, which induces MUC-2 and MUC-5AC gene expres-
sion in the lung, and its receptor, IL-9Ra, were expressed at
variable levels in all cases of PMP with increased IL-9 expression in
the epithelial PMP cells compared with adenocarcinoma. It is
conceivable that the differential IL-9 expression in PMP might
contribute to an autocrine loop leading to goblet cell hyperplasia.
The availability of cultured PMP cells will facilitate future
understanding of the role of IL-9 in mucin production.
Although originating in the appendix, the disease progression of
PMP is very different from other neoplasia arising from other
hindgut sites. However, the observations of this study have led us
to postulate that there are some molecular pathways common to
both PMP and colorectal adenocarcinoma. The majority of
colorectal adenocarcinomas develop through the adenoma–
carcinoma sequence, a multi-stage process of molecular aberra-
tions and mutations in key oncogenes and tumour suppressor
genes (Vogelstein et al, 1988; Kinzler and Vogelstein, 1998). In
common with the majority of colorectal adenocarcinoma, PMP
probably arises through an adenoma, specifically an appendiceal
adenoma, but disseminates throughout the abdominal cavity,
mainly by peritoneal spread, yet seldom metastasises. Like
colorectal adenocarcinoma, this process is characterised by
increased N-cadherin and decreased E-cadherin expression,
although this may be more exaggerated in PMP and is also
associated with increased vimentin expression. In some PMP cases,
there is perforation of the appendix with potential ‘spillage’ of
adenoma cells (Young, 2004), but it is unclear whether this is a
necessary step in the dissemination of PMP. It is conceivable that
sporadic adenocarcinoma contain a different, perhaps more
expanded, molecular profile to that of PMP that affords the ability
to metastasise – questions that will form future research studies.
This study forms the basis to develop further targeted research
programmes both in in vivo and in vitro PMP systems. Larger
sample sizes are required such that correlations with survival and
other outcomes will be feasible. The genetic regulation of the
biological hallmarks of this unusual disease is the key research
question for future strategies to prevent and/or inhibit the
progression of this debilitating and fatal disease.
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